書籍詳細

1. 高血圧の疫学

P.46 掲載の参考文献

• 1) 厚生省大臣官房統計調査部:昭和36年, 37年成人病基礎調査報告, 昭和39.

• 2) 厚生省公衆衛生局:昭和46年, 47年成人病基礎調査報告, 昭和51.

• 3) 渡辺 定:統計からみた高血圧の予後, 医学シンポジウム, 5, 高血圧, 診 断と治療社, 1962.

• 4) WHO Meeting on the control of hypertension and stroke in the community. Tokyo, 11〜13, March. 1974.

• 5) Akinkube, O.O.:Epidemiology of hypertension and stroke in Africa, WHO meeting, Tokyo, 11-13, March. 1974, より引用.

• 6) 重松逸造:日本人の高血圧, 日本医師会雑誌, 73:641, 1975.

• 7) 加藤寛夫:日本人と日系米人の脳卒中の比較, 日本臨牀, 35:192, 1977.

• 8) Keys, A., Kimura, N., et al.:Epidemiological studies related to coronary heart disease:characteristics of men aged 40-59 in seven country. Acta Med. Scand. Suppl., 460, 1966.
  pubmed

• 9) 循環器管理研究協議会:循環器管理研究協議会報告第1集, 1966.

• 10) 森沢 康:高血圧における心臓所見の推移-疫学的立場から-最新医学, 26:2289, 昭46.

• 11) Scotch, N.A., Geiger, H.J.:Epidemiology of essential hypertension-psychologic and sociocultural factors in etiology-. J. Chro. Dis., 16:1183, 1963.

• 12) 小町喜男:生活環境と脳卒中, 内科, 36:551, 1975.

• 13) 籏野脩一:脳率中の疫学的研究 (世界)-その現状と将来-. 内科, 22: 1204, 1968.

• 14) 広田安夫:脳卒中の疫学, 脳と神経, 23:1241, 1971.

• 15) 勝木司馬之助:脳血管性障害の疫学, 内科シリーズ No. 4. 脳卒中のすべて, 南江堂, 1971.

• 16) Stallones, R.A.:Epidemiology of cerebrovascular disease:-A review-, J. Chron. Dis., 18:859, 1965.
  pubmed

• 17) 森沢 康, 伊藤良雄:疫学面よりみた虚血性心疾患. 最新医学. 29:2, 1974.

• 18) 佐々木直亮:疫学面よりみた食塩と高血圧. 最新医学, 26:2270, 1971.

• 19) Perry, H.M. Jr., Tipton, I. H., Schroeder, H.A., et al.:Variation in the concentration of cadmium in human kidney as a function of age and geographic origin. J. Chron. Dis., 14:259, 1961.
  pubmed

• 20) 柳沢敏幸:心臓・血管病の遺伝学. 心臓, 5:1193, 1973.

• 21) 宮尾定信:本態性高血圧症, 内科, 35:555, 1975.

• 22) 尾前照雄, 竹下司恭:遺伝, 民族, 生活習慣と高血圧. 綜合臨牀, 23:1871, 1974.

• 23) 八木 繁:高血圧, 動脈硬化, 心筋硬塞と遺伝. 内科, 23:678, 1969.

• 24) 大城新蔵:血圧の遺伝学的研究. 体質医研報, 14:225, 1964.

• 25) Dahl, I., K.:In:Essential hypertension. An international symposium. Springer-Verlag, Berlin. 1960.

• 26) 小沢秀樹:脳卒中の地域差と過去の食生活. 日本公衛誌, 15:551, 1968.

• 27) 佐々木直亮:わが国の脳卒中死亡率の地域差と関連のある栄養因子について. 農民栄養調査による分析. 日本公衛志, 7:1137, 1960.

• 28) 児島三郎:秋田地方を中心とした脳卒中の特異性, 日本公衛誌, 13:907, 1966.

• 29) Guyton, A.C. et al.:Arterial pressure regulation, overriding dominance of the kidneys in long-term regulation and in hypertension. Am. J. Med, 52:584, 1972.
  pubmed

• 30) 阿部 裕ほか:塩文明と高血圧, 綜合臨牀, 25:2438, 1976.

• 31) 福田安平:脳卒中, 心発作の疫学的研究, 労働医学研究会, 1970.

• 32) 小町喜男ほか:環境と高血圧, 診断と治療, 62:1719, 1974.

• 33) 佐々木直亮ほか:脳卒中死亡率と気温との関係について, 医学と生物学, 39 (6):182, 1956.

• 34) Kagan, A.:Hypertension and stroke in the community, Proceeding of a WHO meeting held in Tokyo, 11-13. March, 1974. edited by S. Hatano, I. Shigematsu, & T. Strasser, p.97, Geneva, 1976.

• 35) Pickering, G.:Hypertension-Causes, Consequences and Management-. J. & A. Churchill, London, 1970.

• 36) 勝木司馬之助, 重松逸造, 小町喜男, 亀上正邦, 尾前照雄, 上田英雄最近の高血圧・脳卒中対策-WHO循環器疾患東京会議を終えて-. 日本臨牀, 32:3179, 1974.

• 37) 籏野脩一, 重松逸造:集団における高血圧・脳卒中の総合対策-最近のWHO東京会議から-. 日本医事新報, No. 2619:27, 1974.

• 38) Kuller, L., Reisler, D.M.:An explanation for variations in distribution of stroke and arteriosclerotic heart disease among populations and racial groups. Am. J. Epidemiol., 93:1, 1971.
  pubmed

• 39) Kannel, W.B., Melvin, J.S.:Systolic versus diastolic blood pressure and risk of coronary heart discase. Am. J. Cardiol., 27:335, 1971.

• 40) 森沢 康:疫学からみた高血圧学の進歩, 臨床成人病, 6(3):295, 1976.

• 41) 家森幸男:高血圧の新しい基準と対策-WHO高血圧専門委員会から-, 日本臨牀, 36(6):159, 1978.

2. 成因と病態生理

P.61 掲載の参考文献

• 1) Tigerstedt, K.G.and Bergmann, P.G.:Scand Arch. Physiol., 8:223, 1898.

• 2) Goldblatt, H., Lynch, J., Hanzal, R.F., et al.:J. Exper. Med., 59:347, 1934.

• 3) Braun-Menendez, E., Fasciolo, J.C., Leloir, L. F., et al.:J. Physiol., 98:283, 1940.
  pubmed

• 4) Page, I. H. and Helmer, O.M.:J. Exp. Med., 71:495, 1940.
  pubmed

• 5) Boyd, G.W.:Circ. Res., 35:426, 1974.
  pubmed

• 6) Day, R.P. and Luetscher, J. A.:J. Clin. Endocrinol. Metab., 40:1078, 1975.
  pubmed

• 7) 村上和雄, 稲上正:蛋白, 核酸, 酵素22:283, 1977.

• 8) Leckie, B.:Clin. Sci., 44:301,:1973.
  pubmed

• 9) Skinner, S. L., Cran, E. F., Gibson, R., et al.:Am. J. Obstet. Gynecol., 121:626, 1975.

• 10) Sealey, J.E. and Laragh, J.H.:Circ. Res. 36-37:1, 1975.

• 11) Boyd, G. W.:Lancet, 1:215, 1977.

• 12) Weinberger, M.H., Wade, M.B., Aoi, W., et al:Circ. Res., 40 (Suppl.1):1, 1977.

• 13) Boucher, R., Saidi, M. and Genest, J.:Hypertension 72, edited by Genest J. and Koiw E. Springer-Verlag, New York, 1977, p.512.

• 14) Campbell, W., Brooks S.N. and Pettinger, W.A.:Science, 184:994, 1974.
  pubmed

• 15) Semple, P.F. and Morton, J.J.:Circ. Res., 38 (Suppl.II):122, 1976.

• 16) Kono, T., Oseko, F., Shimbo, S., et al.:J. Clin. Endocrinol. Metab., 41:1174, 1975.

• 17) Saruta, T., Saito, I., Nakamura, R., et al.:Jap. Circ. J., 41:887, 1977.
  pubmed

• 18) McCubbin, J.W., DeMoura, R.S., Page, I. H., et al.:Science, 149:1394, 1965.
  pubmed

• 19) Ferrario, C.M., Gildenberg, P.L. and McCubbin, J.W.:Circ. Res. 30:257, 1972.
  pubmed

• 20) Fukiyama, K., McCubbin, J.W. and Pag, I. H.:Clin. Sci., 40:283, 1971.

• 21) Ferrario, C.M. and McCubbin, J.W.:Hypertension-Mechanisms, Diagnosis & Management, edited by Davies, J O., Laragh, J.H. and Selwyn, A. HP Publishing, New York, 1977, p.80.

• 22) Robertson, P.W., Klidjian, A., Harding, L.K., et al.:Am. J. Med., 43:963, 1967.
  pubmed

• 23) Kihara, I., Kitamura, S., Hoshino, T., et al.:Acta. Path. Jap., 18:197, 1968.
  pubmed

• 24) Brunner, H.R., Kirshman, J.D., Sealey, J.E., et al.:Science, 174:1344, 1971.
  pubmed

• 25) Streeten, D.H.P., Anderson, G. H., Freiberg, J.M., et al.:N.Engl. J. Med., 292:657, 1975.

• 26) 保嶋実, 阿部圭志, 青柳春樹, 他:第18回日本腎臓学会総会予講集 p.249, 1975.

• 27) Saruta, T., Saade, A.G. and Kaplan, N.M.:Arch. Intern. Med., 127:621, 1970.

• 28) 金子好宏:日本臨床代謝学会記録, 8:6, 1971.

• 29) Brunner, H.R., Sealey, J.E. and Laragh, J.H.:Am.J.Med., 55:295, 1975.

• 30) Sambhi, M.P., Eggena, P., Barrett, J.D., et al.:Circ.Res., 36-37 (Suppl. 1):28, 1975.

P.77 掲載の参考文献

• 1) Miksche, L.W., Miksche, U. and Gross, F.:Effect of sodium restriction on renal hypertension and on renin activity in the rat. Circ. Res. 27:973, 1970.
  pubmed

• 2) Selye, H., Hall, C.E.and Rowley, E.M.:Malignant hypertension produced by treatment with desoxycorticosterone acetate and sodium chloride. Can. Med. Ass. J. 49:88, 1943.
  pubmed

• 3) Braun-Menendez, E. and von Euler, U.S.:Hypertension after bilateralnephrectomy in the rat. Nature 160:905, 1960.

• 4) Merrill, J.P., Murray, J.E., Harrison, J. H. and Guild, W.R.:Successful homotransplantation of the human kiduey between identical twins. J.A.M.A. 160:277, 1956.

• 5) 阿部圭志, 三輪動, 吉永馨:キニンと血圧調節. 代謝, 8:491, 1971.

• 6) Ward, P.E., Gedney C.D., Dowben, R.M. and Erdos, E.G.:Isolation of membrane-bound renal kallikrein and kininase. Biochem. J. 151:755, 1975.
  pubmed

• 7) Yoshinaga, K., Abe, K. . Miwa, I., Furuyama, T. and Suzuki, C.:Evidence for the renal origin of urinary kinin. Experientia 20:396, 1964.
  pubmed

• 8) Scicli, A.G., Carretero, O.A., Hampton, A., Cortes, P. and Oza, N.B.:Site of kininogenase secretion in the dog nephron. Am. J. Physiol. 230:533, 1976.
  pubmed

• 9) Roblero, J.H., Croxatto, R., Garcia, R., Corthorn, J. and deVito, E.:Kallikrein-like activity in perfusates and urine of isolated rat kidneys. Am. J. Physiol. 231:1383, 1976.

• 10) Webster, M.E. and Gilmore, J.P.:Influence of kallidin-10 on renal function. Am. J. Physiol. 206:714, 1964.
  pubmed

• 11) Bailie, M.D. and Barbour, J.A.:Effect of inhibition of peptidase activity on distribution of intrarenal blood flow. Am. J. Physiol. 228:850, 1975.
  pubmed

• 12) Geller, R.G., Margolius, H.S., Pisano, J.I and Keiser, H.R.:Effects of mineralocorticoids, altered sodium intake, and adrenalectomy on urinary kallikrein in rats. Circ. Res. 31:857, 1972.
  pubmed

• 13) Margolius, H.S., Horwitz, D., Geller, R.G., Alexander, Gill, J.R., et al.:Urinary kallikrein excretion in normal man. Relationships to sodium intake and sodium-retaining steroids. Circ. Res. 35:812, 1974.

• 14) Seino, M., Abe, K., Sakurai, Y., Irokawa, N., et al.:Effect of spironolactone on urinary kallikrein excretion in patients with essential hypertension and in primary aldosteronism. Tohoku J. Exp.Med. 121:111, 1977.
  pubmed

• 15) Marin-Grez, M., Oza, N.B. and Carretero, O.A.:The involvement of urinary kallikrein in the renal escape from the sodium retaining effect of mineralocorticoids. Henry Ford Hospital Med. J. 21(2):85, 1973.

• 16) 阿部圭志, 色川伸夫, 清野正英, 他:本態性高血圧症とkallikrein-kinin 系の研究とくに尿kallikrein-kinin系と renin-angiotensin-aldosterone 系の研究. 日内会誌, 69:483, 1978.

• 17) Croxatto, H.R. and San Martin, N.L.:Kallikrein-like activity in the urine of renal hypertensive rats. Experientia 26:1216, 1970.

• 18) Carretero, O.A., Amin, V.M., Ocholik, T., et all:Urinary kallikrein in rats bred for their susceptibility and resistance to the hypertensive effect salt. A new radioimmunoassay for its direct determination. Circ. Res. 42:727, 1978.

• 19) Margolius, H.S., Geller, R., Pisano, J.J. and Sjoerdsma, A.:Altered urinary kallikrein excretion in human hypertension. Lancet II:1063, 1971.

• 20) Abe, K., Seino, M., Sakurai, Y., et al.:Studies on urinary kallikrein and kinin in essential hypertension. Kininogenases kallikrein 4. edited by Haberland, G.L, Rohen, J.W. and Suzuki, T.:F.K. Schattauer Verlag. Stuttgart-New York 1977, p. 351.

• 21) Gavros, H., Brunner, H.R., Turini, G.A., et al.:Antihypertensive effect of the oral angiotensin converting-enzyme inhibitor SQ 14225 in man. New Engl. J. Med. 298:991, 1978.

• 22) Lee, J.B., Covino, B.G., Takman, B.H., et al.:Renomedullary vasodepressor substance, medullin:Isolation, chemical characterization and physiological properties. Circ. Res. 17:57, 1965.
  pubmed

• 23) Larsson, C. and Anggard, E.:Mass spectrometric determination of prostaglandin E2, F2α and A2 in the cortex and medulla of the rabbit kidney. J. Pharm. Pharmac, 28:326, 1976.

• 24) Terragno, N.A., Terragno, A., McGiff, J.C., et al.:Endogenous prostagladin synthesis inhibitor of the renal cortex:Effects on production of prostacyclin by renal blood vessels. Abstracts of 5th Scientific Meeting of the International Society of Hypertension. p.270.

• 25) Johnston, H.H., Herzog, J.P. & Lauler, D.P.:Effect of prostaglandin E1 on renal hemodymics, sodium and water excretion. Am. J. Physiol., 213:939, 1967.

• 26) Rosenthal, J., Simone, P.G., Silbergleit, A., et al.:Effects of prostaglandin deficiency on natriuresis, diuresis, and blood pressure. Prostaglandins, 5:435, 1974.
  pubmed

• 27) Tobian, L. & O'Donnell, M.:Renal prostagland ins in relation to sodium regulation and hypertension. Federation Proc., 35:2388, 1976.

• 28) Stokes, J. B. & Kokko, J.P.:Inhibition of sodium transport by prostaglandin E across the isolated. perkused rabbit collecting tubule. J. Clin. Invest., 59:1099, 1977.
  pubmed

• 29) Yasujima, M., Abe, K., Chiba, S., et al.:Implication of renal prostaglandin E in urinary sodium excretion. Jap. Circ. J., 42:565, 1978.
  pubmed

• 30) McGiff, J.C., Crowshaw, K., Terragno, N.A., et al.:Release of a prostaglandin-like substance into renal venous blood in response to angiotensin II Circ. Res., 26〜27 (Suppl. I) ;1-121, 1970.

• 31) Larsson , C., Weber, P., Anggard, E., et al.:Arachidonic acid increases and indomethacin decreases plasma renin aclivity in the rabbit. Eur. J. Pharmacol. 28:391, 1974.
  pubmed

• 32) 阿部圭志, 佐藤牧人, 保嶋実, 千葉知, プロスタグランジンと腎, 循環器科 3:442, 1978.

• 33) Berl, T., Raz, A., Wald, H., Horowitz, J. and Czaczkes, W.:Prostaglandin synthesis inhibition and the action of vasopressin;Studies in man and rat. Am. J. Physiol, 232;F529, 1977.
  pubmed

• 34) Abe, K., Yasujima, M., Chiba, S., et al.:Effect of furosemide on urinary excretion of prostaglandin E in normal volunteers and patients with essential hypertension. Prostaglandins. 14:513, 1977.
  pubmed

• 35) Abe, K., Irokawa, N., Yasujima, M., et al.:Kallikrein-kinin system and prostaglandin in the kidney:Their relation to furosemide induced diuresis and to renin-angiotensin-aldosterone system. Circ, Res., 43:254, 1978.
  pubmed

• 36) Abe, K., Seino, M., Yasujima, M., et al.:Studies on renomedullary prostaglandin and renal kallikrein-kinin system in hypertension. Jap. Circ. J., 41:873, 1977.
  pubmed

• 37) Abe, K., Otsuka, Y., Yasujima, M., et al.:Metabolism of PG in man:Effect of furosemide on the excretion of the main metabolite of PGF2α. Prostaglandins, 12:843, 1976.

• 38) Tan, S.Y., Sweet, S. and Mulrow, P.J.:Impaired renal production of prostaglandin E2;A newly identified lesion in human essential hypertension. Prostaglandins 15:139, 1978.

P.94 掲載の参考文献

• 1) Seldin, D.W., et al.:Amer. J. Med., 15:608, 1954.

• 2) Conn, J.W., et al.:J. Amer. Med., Ass., 193:200, 1965.

• 3) Seabold, J.E., et al.:J. Clin. Endocr. & Metab., 42:41, 1976.
  pubmed

• 4) Arnold, J.E. & Healy, J.K.:Amer. J. Med., 47:461, 1967.

• 5) Chauvel, P.J., Beveridge, J. and Stokes, G.S.:Amer. J. Dis. Child., 119:159, 1970.
  pubmed

• 6) Liddle, G.W., Bledsoe, T. and Coppage, W.S.:Aldosterone, A Symposium Organized by CLOMS, E.-E. Baulieu and P. Robel p.353, 1964.

• 7) 福地総逸, 三浦正:内科, 43:155, 1978.

• 8) Sennett, J.A., et al:Circ. Res., 36:Supple. 1, 2, 1975.

• 9) 中嶋凱夫:日腎会誌, 19:321, 1977.

• 10) Dale, S., et al.:Clin. Res., 23:292 A, 1974.

• 11) 福地総逸, 他:ホと臨, 23:451, 1975.

• 12) Sekihara, H., et al.:J. Clin. Endocr.& Metab., 43:1078, 1976.
  pubmed

• 13) Sennett, J.A., et al.:Circ. Res., 41:260, 1977.
  pubmed

• 14) 福地総逸, 他:日腎会誌, 16:893, 1974.

• 15) Eich, R.H., et al.:Circulation, 34:299, 1966.
  pubmed

• 16) Margolius, H.S., et al.:Circ. Res., 35:820, 1974.
  pubmed

P.111 掲載の参考文献

• 1) 永津:高血圧の成因における神経・血管系-血液ドーパミンβ水酸化酵素 (DBH) を中心として, 最新医学 31, 439-446, 1976.
  Medical*Online

• 2) Weinshilboum, R.M., et al:Serum dopamine-β-hydroxylase activity:Sibling-sibling correlation. Science, 181, 943-945, 1973.

• 3) Planz, G., et al.:Correlation between increased dopamine-β-hydroxylase activity and catecholamine concentration in plasma:Determination of acute changes in sympathetic activity in man. Euro P.J. Clin. Pharmacol. 8, 181-188, 1975.

• 4) Lake, C.R., et al.:Dopamine-β-hydroxylase in hypertensive and normotensive subjects. Circ. Res. 41, 865-869, 1977.

• 5) 宮原他:本態性高血圧症, 成因としてのカテコールアミンの動態, 最新医学 31, 447-457, 1976.
  Medical*Online

• 6) 飯村他:本態性高血圧症, 内分泌系と昇圧機序:カテコラミン, 綜合臨牀 25, 2477-2483, 1976.

• 7) Mendlowitz, M. & Vlackakis, N.D.:The catecholamines in essential hypertension. Am. Heart J. 91, 378-382, 1976.

• 8) Iimura, O., et al.:Sympathetic nerve activity in patients with essential hypertension-A comparison of the activity among patients with labile and stable or low, normal and high renin essential hypertension. Jap. Circ. J. 42, 599-607, 1978,
  pubmed

• 9) 永津:モノアミン定量法, 日本臨牀, 36, 8-12, 1978.
  Medical*Online

• 10) Louis, W.J., et al.:Plasma catecholamine, dopamine-beta-hydroxylase, and renin levels in essential hypertension. Ciric. Res. 34, 35, Suppl. 1, I-57-63, 1974.

• 11) Esler, M., et al.:Agreement among three different indices of sympathetic nervous system activity in essential hypertension. Mayo Clin. Proc. 52, 379-382, 1977.
  pubmed

• 12) Sever, P. S., et al.:Plasma-noradrenaline in essential hypertension. Lancet i, 1078-1081, 1977.
  pubmed

• 13) Lake, C.R., et al.:Age-adjusted plasma norepinephrine levels are similar in normotensive and hypertensive subjects. New Engl. J. Med. 296, 208-209, 1977.
  pubmed

• 14) Pedersen, E.B. & Christensen, N.J.:Catecholamine in plasma and urine in patients with hypertension determined by double-isotope derivative techniques. Acta Med. Scand. 198, 373-377, 1975.
  pubmed

• 15) De Champlain, J. & Cousineau, D.:Lack of correlation between age and circulating catecholamine in hypertensive patients. New Engl. J. Med. 297, 672, 1977.
  pubmed

• 16) Kopin, I.J.:NIH Conference;Plasma levels of norepinephrine. Ann. Intern. Med. 88, 671-680, 1978.

• 17) Lamprecht, F., et al:Serum dopamine-β-hydroxylase:Constancy of levels in normotensive adults and decreases with develoopment of blood pressure elevation. Life Sci. 19, 749-754, 1975.

• 18) DeQuattro, V., et al.:Increased plasma catecholamine concentrations and vas deferens norepinephrine biosynthesis in men with elevated blood pressure. Circ. Res. 36, 118-126, 1975.
  pubmed

• 19) 家森他:高血圧の発症・維持機構と神経・血管系, 最新医学 31, 431-438, 1976.
  Medical*Online

• 20) 飯村:脳内アミンと筒血圧, 代謝 6, 468-474, 1972.

• 21) Frohlich, E.D.:The adrenergic nervous system and hypertension of the rat. Mayo Clin. Proc. 52, 361-368, 1977.

• 22) Reid, J.L. & Dollery, C.I.:Central and peripheral catecholamine metabolism in circulatory control. Cardiology 61, Suppl. 1, 113-124, 1976.

• 23) 宮原:カテコラミン, (上田英) 編, 高血圧のすべてp.84, 南江堂, 東京, 1973.

• 24) Mendlowitz, M.:Vascular reactivity in systemic arterial hypertension. Am. Heart J. 85, 252-259, 1973.
  pubmed

• 25) Miyahara, M., et al.:Studies on the role of sympathetic nervous system in the mechanism of essential hypertension. Jap. Circ. J.41, 228-236, 1977.
  pubmed

• 26) 宮原他:心血行力学的にみた高血圧の病態生理と治療, 治療, 57, 1848- 1854, 1975.

• 27) Esler, M., et al.:Mild high-renin essential hypertension. Neurogenic human hypertension? New Engl. J. Med. 296, 405-411, 1977.
  pubmed

• 28) DeQuattro, V., et al:Sympathetic nerve hyperactivity in high-renin hypertension. Effect of saralasin infusion. Mayo Clin. Proc. 52, 369-373, 1977.
  pubmed

• 29) Eich, R. H., et al.:Hemodynamics in labile hypertension. A follow-up study. Circulation 34, 299-307, 1966.
  pubmed

• 30) Julius, S. & Sckork, M.A.:Borderline hypertension-A critical review. J. Chron. Dis. 23, 723-754, 1971.

3. 二次性高血圧

P.124 掲載の参考文献

• 1) 武田忠直:腎性高血圧, 心臓学, p.509, 朝倉書店, 1978.

• 2) 石井當男:腎性, 腎血管性高血圧症, 臨床循環器病講座. 〔4〕, p.49, 金原出版, 1976.

• 3) Gonard, C., Vallotton & Broyer, M.:Nephron. 11:308, 1973.

• 4) 武田忠直:内科 24:616, 1969.

• 5) Gabriel, R.:Brit, Med. J. 2:999, 1977.
  pubmed

• 6) Guyton, A.C., et al.:Amer. J. Med. 52:584, 1972.
  pubmed

• 7) Brunner, H.R., Kirshman, J.D., Sealey, J.E. & Laragh, J.H.:Science 174:1344, 1971.
  pubmed

• 8) Baer, L., et al.:Ann. Intern. Med. 86:257, 1977.
  pubmed

• 9) Yasujima, M., et al.:Tohoku J. Exp. Med. 116:277, 1975.
  pubmed

• 10) Munoz-Ramirez, H., et al.:Res. Comm. Chem. Pathol. & Pharmacol. 13:649, 1976.

• 11) Ondetti, M.A., et al:Biochemistry. 10:4033, 1971.
  pubmed

• 12) Gavras, H., et al.:New England J. Med. 291:817, 1974.

• 13) Miller, E.D., et al.:Amer. J. Physiol. 228:448, 1976.

• 14) Ferguson, R.K., et al:Lancet 1:775, 1977.
  pubmed

• 15) Case, D.B., et al.:Prog. Cardiovasc. Dis. 21:195, 1978.
  pubmed

• 16) Erdos, E.G.:Amer. J. Med. 60:749, 1976.
  pubmed

• 17) Muirhead, E.E., et al.:J. Lab. & Clin. Med. 67:778, 1966.
  pubmed

• 18) Lee, J.B, , et al:Circulat. Res. 17:57, 1965.
  pubmed

• 19) Seino, M., et al.:Tohoku J. Exp. Med. 116:359, 1975.
  pubmed

• 20) Ueda, H., et al:Jap. Heart J. 9:142, 1968.
  pubmed

• 21) Bookstein, J.J., et al.:J. Amer. Med. Ass. 220:1225, 1972.

• 22) 金子好宏ほか:最新医学. 27:351, 1972.

• 23) Melman, A., et al.:J. Urol. 117:145, 1977.
  pubmed

• 24) Scherer, B., et al.:Klin. Wschr. 55:907, 1977.
  pubmed

• 25) 武田忠直:内科 31:234, 1973.

• 26) Robertson, P.W., et al.:Amer. J. Med. 43:963, 1967.
  pubmed

• 27) Kihara, I, et al.:Acta Path. Japan. 18:197, 1968.

• 28) Conn, J.W., et al.:Arch. Intern. Med. 130:682, 1972.
  pubmed

• 29) Takeda, T.:Jap. Circul. J. 39:767, 1975.

• 30) Diethelm, A.G., et al.:Surg. Gynecol. & Obstet. 140:161, 1975.
  pubmed

P.144 掲載の参考文献

• 1) Conn, J.W.:Part II. Primary aldosteronism, a new clinical syndrome. J. Lab. Clin. Meb. 45:6-17, 1955.

• 2) George, J.M., et al.:The syndrome of primary aldosteronism. Amer. J. Med. 48:343-356, 1970.
  pubmed

• 3) 尾前照雄ほか:Conn 症候群の成因と術後経過. 日内会誌. 61:1011-1012, 1972.

• 4) 尾前照雄, 川崎晃一:水電解質と高血圧. 日本臨床代謝学会記録 (VIII) 23- 27, 1971.

• 5) 川崎晃一:いわゆる原発性アルドステロン症の病態生理に関する知見. 福岡医誌, 61:82-104, 1970.

• 6) Schambelan, M., et al.:Circadian rhythm and effect of posture on plasma aldosterone concentration in primary aldosteronism. J. Clin. Endocrinol. Metab. 43:115-131, 1976.
  pubmed

• 7) Conn, J.W., et al.:Primary aldosteronism:Present evaluation of its clinical characteristics and of the results of surgery. In Baulieu, E.E. and Robel, P.:Aldosterone. pp. 327-352, Blackwell Scientic Publications, Oxford, England, 1964.

• 8) 鳥飼龍生:高血圧と内分泌. 日内会誌. 58:579-592, 1969.

• 9) 熊谷 朗ほか:本邦における過去10年間の原発性アルドステロン症307例の実態日内泌誌. 49:1362-1378, 1973.

• 10) Williams, G.H., et al.:In Harrison's Principles of internal medicine, 8th ed., pp. 538-542, McGraw-Hill, New York, 1977.

• 11) Conn, J.W., et al.:Normokalemic primary aldosteronism. A detectable cause of curable essential hypertention. J.A.M.A. 193:200-206, 1965.

• 12) Glaz, E. and Vecsei, P.:Aldosterone. p.153, Pergamon Press. Oxford, 1971.

• 13) Kaplan, N.M.:Primary aldosteronism with malignant hypertention. N. Eng. J. Med. 269:1282-1286, 1963.

• 14) Aloia, J.F. and Beutow, G.:Malignant hypertension with aldosterone producing adenoma. Amer. J. Med. Sci. 268:241-245, 1974.
  pubmed

• 15) Conn, J.W.:Hypertension, the potassium ion and impaired carbohydrate tolerance. N. Eng. J. Med. 273:1135-1142, 1965.

• 16) Kawasaki, T., et al.:Individual renin-aldosterone responses of clinically healthy young Japanese men to dietary sodium and posture.Jpn.Heart J. 20:631-642, 1979.
  pubmed

• 17) Kem, D.C., et al.:Saline suppression of plasma aldosterone in hypertension. Arch. Intern. Med. 128:380-386, 1971.
  pubmed

• 18) Biglieri, E.G., et al.:Useful parameters in the diagnosis of primary aldosteronism. J.A.M.A. 178:19-22, 1961.

• 19) 川崎晃一, 尾前照雄:抗アルドステロン剤の適応.臨床と研究.48:1656- 1661, 1971.

• 20) 福地総逸ほか:原発性アルドステロン症のアルドステロン分泌に及ぼす splr-onolactone の効果. 内科 38:658-661, 1976.

• 21) 河野雄平ほか:Conn症候群における Angiotensin II analogue の効果.第40回日本循環器学会九州地方会口演, 昭和51年7月, 福岡.

• 22) Horton, R. and Finck, E.:Diagnosis and localization in primary aldosteronism. Ann. Intern. Med. 76:885-890, 1972.
  pubmed

• 23) 福地総逸ほか:腎静脈また副腎静脈中アルドステロン含量測定による原発性 アルドステロン症の副腎腺腫の局在の診断. 日内泌誌 49:865-870, 1973.

• 24) Conn, J.W.:Primary aldosteronism:photoscanning of tumors after administration of 131I-19-iodocholesterol Arch. Intern. Med. 129:417-425, 1972.

• 25) Kojima, M., et al.:New adrenal-scanning agent. J. Nucl. Med. 16:666-668, 1975.
  pubmed

• 26) 福地総逸:原発性アルドステロン症. 臨床科学 14:926-933, 1978.

• 27) Kehlet, H., et al.:Comparative study of ultrasound, 131I-19-iodocholesterol scintigraphy, and aortography in localising adrenal lesions. Brit. Med. J. 2:665-667, 1976.
  pubmed

• 28) 塩之入洋ほか:両側副腎皮質腺腫の存在を手術前に診断した原発性アルドステロン症の1例. 日腎誌 20:1-11, 1978.

• 29) Ganguly, A., et al.:Anomalous postural response of plasma aldosterone concentration in patients with aldosterone-produciong adrenal adenoma. J. Clin. Endocrinol. Metab. 36:401-404, 1973.
  pubmed

• 30) Ferris, J.B., et al.:Hypertension with aldosterone excess and low renin:preoperative distinction between patients with and without adrenocortical tumor. Lancet 2:995-1000, 1970.

• 31) Conn, J.W.:Primary aldosteronism. In Genest, J., et al.:Hypertention, physiopathology and treatment. pp. 768-780, McGraw-Hill Book Comp. New York, 1977.

• 32) 中嶋凱夫, 福地総逸:原発性アルドステロン症, 鎮目和夫編, 内科シリーズ, 副腎疾患のすべて, pp. 120-131, 南江堂, 東京, 1978.

• 33) Omae, T., et al.:Hyperaldosteronism due to adrenocortical adenoma and adenomatous hyperplasia. Endocrinol. Japon. 18:57-66, 1971.

• 34) 土山秀夫:II-1-A, 球状帯の過形成から腺腫成立への過程-aldosterone 症を中心として-熊本悦明ほか編, 副腎皮質の形態と機能, pp.77-89. 南江堂, 東京, 1970.

• 35) Kawasaki, T., et al.:Remission of recurrent hyperaldosteronism resulting from sub-total adrenalectomy of adenomatous hyperplastic adrenal glands. J. Clin. Endocrinol. Metab. 33:474-480, 1971.

• 36) Ferriss, J.B., et al.:Clinical, bicchemical and pathological features of low-renin ("Primary") hyperaldosteronism. Amer. Heart J. 95:375-388, 1978.
  pubmed

• 37) Kawasaki, T., et al.:Influence of unilateral adrenalectomy on reninamgiotensin-aldosterone system in primary aldosteronism.
  pubmed

P.156 掲載の参考文献

• 1) Manger, W.M. & Gifford, R. W.:Pheochromocytoma. Springer-Verlag, New York, Heidelberg, Berlin. 1977.

• 2) 佐藤辰男:褐色細胞腫とその周辺. 三浦清, 清水直容, 大沢仲昭編:副腎生 殖内分泌 (I), 42-58頁. 医歯薬出版株式会社, 東京, 1976.

• 3) 佐藤辰男ほか:甲状腺髄様癌と Sipple 症候群. 臨床科学11, 961, 1975.

• 4) 梅田照久ほか:副腎髄質腫瘍. 臨床科学13, 1378, 1977.

• 5) Kobayashi, K., et al.:Exocytosis plays an important role in catecholamine secretion from human pheochromocytoma. Clin. Chim. Acta, 85, 159, 1978.
  pubmed

P.174 掲載の参考文献

• 1) Cushing's disease as a psychosomatic disorder. A report of ten cases. Gifford, S.:Medicine. 49:397, 1970.
  pubmed

• 2) Arce, B., Licea, M., Hung, S. and Padron, R.:Familial Cushing's syndrome. 87:139, 1978.
  pubmed

• 3) Tyrell, J.B., R.M. Brooks, P.A. Fitzgerald, P.B.Cofoid, P.H. Forsham and C.B. Wilson:Selective trans-sphenoidal resection of pituitary microadenomas. New Engl. J. Med. 298:753, 1978.

• 4) 横山正夫:副腎皮質の形態と機能, 熊本明, 笹野伸昭, 土山秀夫編, 南山堂 p.249, 1975.

• 5) Meador, C.K., Bowdoin, B., Owen, W. Crawford Jr. and Farmer, T.A. Jr.:Primary adrenocortical nodular dysplasia:A rare cause of Cushing's syndrome. J. Clin. Endocrinol. & Metab. 27:1255, 1967.

• 6) Weigienka, L.C., K.P. Wuepper, L.E. Komarmy and P.H. Forsham:Cushing's syndrome with adrenal medullary insufficiency and adrenal antibody.:Lancet 1:741, 1966.

• 7) 西川光夫:内分泌異常の臨床. 日本内科学会誌 64:1335, 1975.

• 8) Pearse. A.G.E. and Polak, J.M.:Endocrine tumors of neural crest origin. Neurolophams, Apudomas and He APUD concept. Med. Biol. 52:3, 1974.

• 9) Martin, M.M. and Hammon, B.L:Pattern of urinary excretion of steroids in Cushing's syndrome. J. Clin. Endocrinol.&Metab. 26:257, 1966.

• 10) Biglieri, E.G., Slaton, P.E., Schambelan, M., Kronfield, S. J.:Hypermineralocorticoidism. Am. J. Med. 45:170, 1968.
  pubmed

• 11) Schambelan, M., Slaton, P.E. and Biglieri, E.G.:Mineralocorticoid production in hyperadrenocorticism:role in pathogenesis of hypokalemic alkalosis. Am. J. Med. 51:299, 1971.
  pubmed

• 12) 岸谷正雄, 臼倉教臣, 竹田亮祐, 大江国広, 太田五六, 織田邦夫:突然死した高令のCushing症候群の1剖検例診断と治療. 64:703, 1976.

• 13) Paracardiac lipomatosis in exogenous Cushing's syndrome. Thorax. 28:653, 1973.
  pubmed

• 14) Regestein, Q.R., Rose, L I. and Williams, G. H.:Psychopathology in Cushing's syndrome. Arch. Int. Med. 130:114, 1972.

• 15) deAsis, D.N. Jr. and Samaan, N.A.:Feminizing adrenocortical carcinoma with Cushing's syndrome and pseudohyperparathyroidism. Arch. Int. Med. 138:301, 1978.

• 16) Luton, J-P., Thieblot, P., Valcke, J-C., Mahoudeau, J.A. and Bricaire, H.:Revesible gonadotropin defficieny in male Cushing's disease. J. Clin. Endocrinol. & Metab. 45:488, 1977.

• 17) 鎮目和夫 他:原生省特定疾患「下垂体機能障害研究班」昭和49年, 50年度総括研究事業報告書.

• 18) Ross, E.J., Marshall-Jones, P. and Friedman, M.:Cushing's syndrome:diagnostic criteria. Quart. J. Med. 35:149, 1966.

• 19) 三浦清 他:Cushing 症候群と高血圧ホルモンと治療. 19:457, 1971.

• 20) Baxter, J.D. and P.H. Forsham:Tissue effects of glucocorticoids. Am. J. Med. 53:573, 1972.

• 21) Dalakos, T.G., Elias, A.N., Anderson, G.H. Jr., Streeten, D.H.P. and Schroeder, E.T.:Evidence for an angiotensinogenic mechanism of the hypertension of Cushing's syndrome. J. Clin. Endocrinol. & Metab. 46:114, 1978.

• 22) Mantero, F., Armanini, D. and Boscaro, M:Plasma renin activity and urinary aldosterone in Cushing's syndrome. Horm. Metab. Res.:65, 1978.
  pubmed

• 23) Plotz, C.M., Knowlton, A.I. and Ragan, C.:Natural history of Cushing's syndrome. Am. J. Med. 13:597, 1952.
  pubmed

• 24) Olsen, N.J., Fang, V.S. and De Groot, L.J.:Cushing's syndrome due to adrenal adenoma with persistent diurnal cortisol secretory rhythm. Metabolism. 27:695, 1978.
  pubmed

• 25) Ganguly, A., J.B. Stanchfield, T.S. Roberts, C.D. West and F. H. Tyler:Cushing's syndrome in a patient with an empty sell a turcica and amicroadenoma of the adrenohypophysis. Am. J. Med. 60:306, 1976.

• 26) Snals, A.G., Kloppenborg, P.W., Njo, K.T., Knochen, J.M. and Ruland, C.M.:Alcohol-induced Cushingod syndrome. Brit. Med. J. 2:1298, 1976.

• 27) Brooks, R.V., Jeffcoate, S.L., Lundon, D.R., Prunty, F.T.G. and Smith, P.M.:Intermittent Cushing's syndrome with anomalous response to dexamethasone. J. Endocrinol. 36:53, 1966.

• 28) Bailey, R. E.:Periodic hormonogenesis. A new phenomenon. Periodicity in function of a hormone-producing tumor in man. J. Clin. Endocrinol, & Metab. 32:317, 1971.

• 29) Miura, K., Aida, M., Mihara, A., Kato, K., Ojima, M., Demura, R., Demura, H. and Okuyama, M.:Treatment of Cushing's disease with reserpine and pituitary irradiation. J. Clin. Endocrinol. & Metab. 41:511, 1975.

• 30) Krieger, D.T., Amorosa, L. and Linick, L.:Cyproheptadine-induced remission of Cushing's syndrome. New Engl. J. Med. 293:893, 1975.

P.184 掲載の参考文献

• 1) Keith, J.D., Rowe, P. Vlad:Heart Disease in infancy and childhood. MacMillan Pub. Co. 3rd Edit.

• 2) 井上正:大動脈の外科-先天的大動脈疾患の外科第19回日本医学会総会誌 S'-35, 25-30, 1975.

• 3) 松尾準雄他:乳児期の先天性心疾患(3), 小児科治療. 37:601-618, 1973.

• 4) Burrington, J.D.:Response to experimental coarctation of the aorta and pulmonic stenosis in fetal lamb. J. Thorac. Cardiovac. Surg. 75:819-826, 1978.

• 5) 進藤剛毅:乳児における大動脈縮窄症の形態学的研究, 日胸外会誌. 25: 1022-1034, 1977.

• 6) 上野明:大動脈手術の十年遠隔成績, 外科. 14:1691-1698, 1969.

• 7) Shinebourne, E. A., et al.:Coarctation of the aorta in fancy and child-food. Brit. Heart J. 38:375-381, 1976.

• 8) Ibarra-Perez, C., et al.:Recoarctation of the aorta. Nineteen year clinical experience. Am. J. Cardiol. 23:778-786, 1969.
  pubmed

• 9) Hamilton, D.J.:Early and late results of aortoplasty with a left subclavian fiap for coarctation of the aorta in infancy. J. Thorac. Cardiovasc. Surg. 75:699-704, 1978.

• 10) 小出桂三:大動脈炎症候群調査研究班, 昭和50年度研究報告書. 54-58, 1976.

• 11) 上野明:同上, 151-154, 1976.

• 12) 同上他:腎血管性高血圧の手術成績と手術適応. 手術. 31:263-271, 1977.

• 13) 多田裕輔, 上野明:大動脈炎症候群の外科治療. 現代医学. 8:1198-1223, 1976.

4. 本態性高血圧

P.199 掲載の参考文献

• 1) Frank, E.:Bestehen Beziehungen zwischen chroma缶nen System undder chronischen Hypertonie des Menschen? Ein kritischer Beitrag zu der Lehre von der physio-pathologischen Bedeutung des Adrenalins. Deutsch. Arch. Klin. Med. 103:397, 1911.

• 2) 柳瀬敏幸:内科臨床遺伝学, 罹病性の遺伝的解析. 日内会誌. 59:917, 1970.

• 3) Pickering, G.W.:High Blood Pressure. Grune & Stratton, New York, 1955 (p. 244)

• 4) Dustan, H.P., Tarazi, R.C. and Bravo, E.L.:Physiologic characteristics of hypertension. Am. J. Med. 52:610, 1972.
  pubmed

• 5) 田中敏行, 池田正男:本態性高血圧における循環動態, 日本臨床. 31:3150, 1973.
  Medical*Online

• 6) Wallace, J.M.:Hemodynamic lesions in hypertension. Am. J. Cardiol. 36:671, 1975.

• 7) Freis, E.D.:Salt, volume and the prevention of hypertension. Circulation. 53:589, 1976.
  pubmed

• 8) Tarazi, R.C.:Hemodynamic role of extracellular fluid in hypertension. Cir. Res. 38:Suppl II-73, 1976.

• 9) Eich, R.H., et al.:Hemodynamics in labile hypertension. A follow-up study. Circulation. 34:299, 1966.
  pubmed

• 10) Weiss, Y. A., et al.:Repeat hemodynamic determinations in borderline hypertension. Am. J. Med. 64:382, 1978.
  pubmed

• 11) Carey, R.M. and Ayers, C.R.:Labile hypertension. Precursor of sustained essential hypertension?Am. J. Med.61:811, 1976.
  pubmed

• 12) Ibrahim, M.M., et al.:Hyperkinetic heart in severe hypertension:A separate clinical hemodynamic entity. Am. J. Cardiol.35:667, 1975.
  pubmed

• 13) 稲垣義明, 斉藤俊弘:高血圧の血行動態, 臨床的立場から, 最新医学.31: 468, 1976.

• 14) Tarazi, R.C., et al.:Plasma volume and chronic hypertension. Relationship to arterial pressure levels in different hypertensive diseases. Arch. Int. Med. 125:835, 1970.

• 15) Spark, R.F.:Low renin hypertension and the adrenal cortex. New Engl. J. Med. 287:343, 1972.
  pubmed

• 16) Editorial:Low renin"Essential"hypertension. A variant of classic primary aldosteronism? Arch. Int. Med. 135:347, 1975.

• 17) Kuramoto, K., et al.:Hemodynamics in the juvenile hypertension with special reference to the response to propranolol.Jpn. Cir.J.32:981, 1968.

• 18) Julius, S., et al.:Abnormalities of plasma volume in borderline hypertension. Arch. Int. Med. 127:116, 1971.

• 19) Julius, S. and Esler, M.:Autonomic nervous cardiovascular regulation in borderline hypertension. Am. J. Cardiol 31:685, 1975.

• 20) Julius, S., Pascual, A.D., and London, R.:Role of parasympathetic inhibition in the hyperkinetic type of borderline hypertension. Circulation. 44:413, 1971.

• 21) Safar, M.E., et al.:The pressure-volume relationship in normotensive and permanent essential hypertensive patients. Clin. Sci. Mol. Med. 50:207, 1976.
  pubmed

• 22) Emery, A.C. Jr., et al.:"Stress" polycythemia and hypertension. JAMA. 229:159, 1974.
  pubmed

• 23) Chrysant, S.G., et al.:Pathophysiologic significance of"stress"or relative polycythemia in essential hypertension. Am. J. Cardiol, 37:1069, 1976.
  pubmed

• 24) Laragh, J.H.:Vasoconstriction-volume analysis for understanding and treating hypertension:The use of renin and aldosterone profiles. Am. J. Med. 55:261, 1973.
  pubmed

• 25) Kaplan, N.M.:Renin profiles. The unfulfilled promises. JAMA. 238:611, 1977.
  pubmed

• 26) Birkenhager, W.H. and Schalekamp, M.A.D.H.:Control mechanism in essential hypertension. Elseveir, Amsterdam. 1976. (p.95)

• 27) Dunn, M.J.and Tannen, R.L.:Low renin hypertension.In:Genest, J., Loiw, E. and Kuchel, O. (Ed.):Hypertension. McGrraw-Hill, New York, 1977 (p.349).

• 28) Ferriss, J.B., et al.:Low-renin ("primary") hyperaldosteronism. Am. Heart J. 95:641, 1978.
  pubmed

• 29) Tarazi, R.C., Dustan, H.P. and Frohlich, E.D.:Relation of plasma to interstitial fluid volume in essential hypertension. Circulation. 40:357, 1969.
  pubmed

• 30) Ibsen, H. and Leth, A.:Plasma volume and extracellular fluid volume in essential hypertension. Acta Med. Scand. 194:93, 1973.

• 31) Dissmann, Th., et al.:Das Erythrocyten-und Plasmavolumen sowie die Relation zwischen Korperhamatokrit und venosem Hamatokrit in verschiedenen Stadien der essentiellen und bei renovascularer Hypertonie. Klin. Wochenschr. 49:915, 1971.

• 32) Parving, H-H. and Gyntelberg, F.:Transcapillary escape of albumin and plasma volume in essential hypertension. Cir. Res. 32:643, 1973.

• 33) Ulrych, M., et al.:Cardiac output and distribution of blood volume in central and peripheral circulations in hypertensive and normotensive man. Br. Heart J. 31:570, 1969.
  pubmed

• 34) Ellis, C.N. and Julius, S.:Role of central blood volume in hyperkinetic borderline hypertension. Br. Heart J. 35:450, 1973.
  pubmed

• 35) Safar, M.E., et al.:Cardiopulmonary blood volume in borderline hypertension. Clin. Sci. Mol. Med. 47:153, 1974.
  pubmed

• 36) Tarazi, R.C., et al.:Cardiac factor in hypertension. Cir. Res. 34-35:Suppl. I-213, 1974.

• 37) Walsch, J.A., Hyman, C. and Maronde, R.F.:Venous distensibility in essential hypertension. Cardiovas Res. 3:338, 1969.

• 38) London, G.M., et al.:Total effective compliance of the vascular bed in essential hypertension. Am. Heart J. 95:325, 1978.
  pubmed

• 39) Hypertension and Coronary Heart Disease:Classification and Criteria for Epidemiologigal Studies. First Report of the Expert Commitee on Cardiovascular Diseases and and Hypertension. WHO Technical Report Series. No. 168, 1959.

• 40) Arterial Hypertension:Report of a WHO Expert Committee. WHO Technical Report Series No. 628, 1978.
  pubmed

• 41) Joint National Commitee on Detection, Evaluation and Treatment of High Blood Pressure:Report of the joint national commitee on detection, evaluation and treatment of high blood pressure. A cooperative study. JAMA. 237:255, 1977.

• 42) Arterial Hypertension and Ischemic Heart Disease. Preventive Aspects. Report of an Expert Commitee. WHO Technical Report Series. No. 231, 1962.

• 43) 東京大学3内科高血圧研究会:高血圧患者診療基準に関する試案.最新医学 22:2027, 1967.

5. 悪性高血圧

P.213 掲載の参考文献

• 1) Valhard, F. und Fahr, T.:Die Brightsche Nieren Krankheit. Klinik, Pathologie und Atlas. Verlag von Julius Springer, Berlin, 1914.

• 2) Wagener, H.P. and Keith, N.M.:Case of marked hypertension, adequate renal function and neuroretinitis. Arch. Int. Med. 34:374, 1924.

• 3) Keith, N.M., Wagener, H.P. and Kernohan, J.W.:The syndrome of malignant hypertension. Arch. Int. Med. 41:141, 1928.

• 4) Ask-Upmark, E.:Uber juvenile maligne Nephrosklerose und ihr Ver- haltnis zu Storungen in der Nierenentwicklung. Acta path. microbiol. scand. 6:383, 1929. (文献11による).

• 5) Longscope, W.T.:Chronic bilateral pyelonephritis:its origin and its association with hypertension. Ann. Intern. Med. 11:49, 1937.

• 6) MacMahon, H.E., Close, H. G. and Hass, G.:Cardiovascular renal changes associated with basophil adenoma of anterior lobe of the pituitary (Cushing's syndrome). Am. J. Path.10:177, 1934.
  pubmed

• 7) Schottstaedt, M.F. and Sokolow, M.:The natural history and course of hypertension with papilledema (malignant hypertension). Am. Heart J. 45:331, 1953.
  pubmed

• 8) Dustan, H.P., Schneckloth, R. E., Corcoran, A. C. and Page, I.H.:The effectiveness of long-term treatment of malignant hypertension. Circulation 18:644, 1958.
  pubmed

• 9) Harington, M., Kincaid-Smith, P. and McMichael, J.:Results of treatment in malignant hypertension. A seven-year experience in 94 cases. Brit. Med. J. ii:969, 1959.

• 10) Milliez, P.:Tcherdakoff, P., Samarco, P. and Rey, L.P.:The natural course of malignant hypertension. in Essential Hypertension:An International Symposium, ed. by Bock, K.D. and Cottier, P.T., p. 214, Springer, Berlin, 1960.

• 11) Pickering, G.:High blood pressure, 2nd Ed.,J & A Churchill, London, 1968.

• 12) Brust, A.A., Perera, G.A. and Wilkins, R.W.:JAMA 166:640, 1958. (文献10による)

• 13) Kincaid-Smith, P., McMichael, J. and Murphy, E.A.:The clinical course and pathology of hypertension with papilloedema (malignant hypertension). Q, Jl Med. 27:120, 1958.(文献11による)

• 14) Kaplan, N.M.:Primary aldosteronism with malignant hypertension. N. Engl. J. Med. 269:1282, 1963.
  pubmed

• 15) McAllister, R.G., Van Way, C.W., Dayani, K., Anderson, W.J., Temple, E., Michelikis, A.M., Coppage, W.S. and Oates, J.A.:Malignant hypertension:Effect of therapy on renin and aldosterore. Circ. Res. 28&29 (suppl. II):II-160, 1971.

• 16) 鴫谷亮一, 土屋幸彦:本態性高血圧および悪性高血圧の診断, 上田英雄編 「高血圧のすべて」, p. 125, 南江堂, 東京, 1973.

• 17) Brain, M.C., Dacie, J.V. and Hourihane, D.O'B.:Microangiopathic hemolytic anaemia:the possible role of vascular lesions in pathogenesis. Brit. J. Hemat. 8:358, 1962.

• 18) Gavras,H., Oliver, N., Aitchison, J., Begg, C., Briggs, J.D., Brown, J.J., Horton, P.W., Lee, F., Lever, A.F., Prentice, C. and Robertson, J.I.S.:Abnormalities of coagulation and the development of malignant phase hypertension. Kidney International 8:S-252, 1975.

• 19) Laragh, J.H., Ulik, S., Januszewicz, V., Deming, Q.B., Kelly, W.G. and Lieberman, S.:Aldosterone secretion and primary and malignant hypertension. J. Clin. Invest. 39:1091, 1960.

• 20) Weinberger, M.H., Dowdy, A. J., Nokes. G.W. and Luetscher, J.A.:Plasma renin activity and aldosterone secretion in hypertensive patients during high and low sodium intake and administration of diuretic. J. Clin. Endocr. 28:359, 1968.
  pubmed

• 21) Creditor, M.C. and Loschky, U.K.:Plasma renin activity in hypertension. Am. J. Med. 43:371, 1967.
  pubmed

• 22) DelGreco, F., Simon, N.M., Goodman, S. and Roguska, J.:Plasma renin activity in primary and secondary hypertension. Medicine 46:475, 1967.

• 23) Mohring, J., Mohring, B., Naumann, H.J ., Philipp, A., Homsey, E., Orth, H., Danda, G., Kazda, S. and Gross, F.:Salt and water balance and renin activity in renal hypertension of rats. Am. J. Physiol. 228:1847, 1975.

• 24) Matsunaga, M., Yamamoto, J., Hara, A., Ogino, K., Yamori, Y. and Okamoto, K.:Plasma renin and vascular lesion in the stroke-prone spontaneously hypertensive rats. Jap. Cir. J. 39:1305, 1975.

• 25) Mohring, J., Mohring, B., Petri, M. and Haack, D.:Vasopressor role of ADH in the pathogenesis of malignant DOC hypertension. Am. J. Physiol. 232:F260, 1977.
  pubmed

• 26) Mohring, J., Mohring, B., Petri, M. and Haack, D.:Plasma vasopressin concentrations and effects of vasopressin antiserum on blood pressure in rats with malignant two-kidney Goldblatt hypertension. Circ. Res. 42:17, 1978.
  pubmed

• 27) 柊山幸志郎, 瀧下修一, 隈本健司, 野田晏宏, 川崎晃一, 尾前照雄:Angio- tensin II analogue によるレニン依存性高血圧の診断. 日本医事新報 2739: 14, 1976.

• 28) Fukiyama, K., Kawasaki, T., Kumamoto, K., Eto, T., Takishita, S., Noda, Y., Kawano, Y., Ueno, M. and Omae, T.:Evaluation for hyperreninism in malignant hypertension by angiotensin II analogue. 5th Scientific Meeting of International Society of Hypertension, Abstracts, p. 89, 1978.

• 29) 川崎晃一, 柊山幸志郎, 藤見催, 隈本健司, 瀧下修一, 野田晏宏, 前田俊朗, 江藤胤尚, 尾前照雄:悪性高血圧の病態と治療. 日本医事新報2783: 10, 1977.

• 30) 瀧下修一, 柊山幸志郎, 野田晏宏, 尾前照雄:Diazoxide による高血圧緊急症の治療. 心臓10:931, 1978.

• 31) Keith, N.M., Wagener, H.P. and Baker, N.W.:Some different types of essential hypertension:their course and prognosis. Am. J. Med. Sci. 197:332, 1939.

• 32) 尾前照雄, 田仲謙次郎, 飯野耕三, 柊山幸志郎, 藤島正敏, 川崎晃一:悪性 高血圧の病態と予後. 綜合臨牀14:1903, 1965.

• 33) Hood , B., Orndahl, G. and Bjork, S.:Survival and mortality in malignant (grade IV) and grade III hypertension. Acta. Med. Scand. 187 291, 1970.

6. 降圧療法

P.226 掲載の参考文献

• 1) Dustan, H.P., Tarazi, R.C., Bravo, E.L.:Diuretic and diet treatment of hypertension. Arch. Int. Med. 133:1007, 1974.

• 2) Begilow, R.S., Pollack, H., et al.:The therapy of hypertension by accelerated sodium depletion. J. Mount Sinai Hosp. 15:223, 1948.

• 3) Novello, F.C., Sprague, J. M.:Benzothiadiazine dioxides as novel diuretics. J. Am. Chem. Soc. 79:2028, 1957.

• 4) Freis, E.D., Wilson, I. M:Potentiating effect of chlorothiazide in combination with antihypertensive agents, preliminary report. Med. Ann. DC. 26:468, 1957.

• 5) Fernandez, P.C., Puschett, J.B.:Proximal tubular actions of metazolone and chlorothiazide. Am. J. physiol. 225:954, 1973.
  pubmed

• 6) Weinman, E. J., Eknoyan, G.:Chronic effects of chlorothiazide on reabsorption by the proximal tubule of the rat. Clin. Sci. Mol Med. 49:107, 1975.
  pubmed

• 7) Clapp, J.R., Robinson, R.R.:Distal sites of action of diuretic-drugs in the dog. Am. J. Physiol. 215:228, 1968.

• 8) Kunau, R.T. Jr., Weller, D.R., Webb, H.L.:Clarification of the site of action of chlorothiazide in the rat nephron. J. Clin. Invest. 56:401, 1975.
  pubmed

• 9) Holzgreve, H.:The pattern of inhibition of proximal tubular reabsorption by diuretics. In"Renal Transport and Diuretics"ed. by Thurau, K., Jahrmarker, H., Springer Verlag, Heidelberg, 229, 1969.

• 10) Thurau, K., Ervin, C., Anderson, W.Jr.:Renal Na-reabsorption and O2-uptake in dogs during hypoxia and hydrochlorothiazide infusion. Proc. Soc. Exp. Biol. Med. 106:714, 1961.

• 11) Duarte, C.G., Chomety, F., Giebisch, G.:Effect of amiloride, ouabain, and furosemide on distal tubular function in the rat. Am. J. Physiol. 221:632, 1971.
  pubmed

• 12) Burg, M., Stoner, L., Cardinal, J., Green, N.:Furosemide effect on isolated perfused tubules. Am. J. Physiol. 225:119, 1973.
  pubmed

• 13) Wilson, I.M, Freis, E.:Relationship between plasma and extracellular fiuid volume depletion and the antihypertensive effect of chlorothiazide. Circulation. 20:1028, 1959.

• 14) Conway, J., Palmero, H.:The vascular effect of the thiazide diuretics. Arch. Int. Med. 111:121, 1963.

• 15) Lund-Johansen, P.:Hemodynamic changes in long-term diuretic therapy of essential hypertension. Acta Medica Scandinavica 187:509, 1970.
  pubmed

• 16) Freis, E.D., Wanko, A., Schnaper, H.W., Frohlich, E.D.:Mechanism of the altered blood pressure responsiveness produced by chlorothiazide. J. Clin. Invest. 39:1277, 1960.
  pubmed

• 17) Frohlich, E.D., Thurman, A. E., Preffer, M.A., Brobmann, G.F., Jacobson, E. D.:Altered vascular responsiveness:Initial hypotensive mechanism of thiazide diuretics. Proc. Soc. Exp. Biol. Med. 140:1190, 1972.

• 18) Abboud, F.M.:Effects of sodium, angiotensin and steroids on vascular reactivity in man. Fed. Proc. 33:144, 1974.

• 19) Leth, A.:Changes in plasma and extracellular fluid volumes in patients with essential hypertension during long-term treatment with hydrochlorothiazide. Circulation 41:709, 1970.

• 20) Tarazi, R.C., Dustan, H.P., Frohlich, E.P.:Long-term thiazide therapy in essential hypertension. Evidence for persistent alteration in plasma volume and renin activity. Circulation 41:709, 1970.

• 21) 海老原昭夫, 田原一二:Thiazide剤の副作用に関する臨床的研究・臨床薬理, 9:45, 1978.

• 22) Reubi, F.C.:Clinical use of furosemide. Ann. New York Acad. Sci. 139:433, 1966.

• 23) Crane, M.G., Harris, J.J., Johns, V.J.:Hyporeninemic hypertension. Am. J. Med. 52:457, 1972.
  pubmed

• 24) Spark, R.F., Melby, J.C.:Hypertension and low plasma renin activity, presumptive evidence for mineralocorticoid excess. Ann. Intern. Med. 75:831, 1971.
  pubmed

• 25) Nemati, M., Mary, C., Kyle, M.S., Freis, E.D.:Clinical study of Ticrynafen. JAMA. 237:652, 1977.

• 26) Stote, R.M., Dubb, J.W., Familiar, R.G., Alexander, F.J.:Ticrynafen, auricosuric antihypertensive diuretic. Clin. Pharmacol. Ther. 23:456, 1978.

• 27) Lau, K., Stote, R.M., Goldberg, M., Agus, Z.S.:Mechanisms of the uricosuric effect of the diuretic tienilic acid (Ticrynafen) in man. Clin. Sci. Mol Med. 53:379, 1977.
  pubmed

P.230 掲載の参考文献

• 1) Moyer, J.H.:Cardiovascular and renal hemodynamic response to reserpine (Serpasil) and clinical results of using this agents for treatment of hypertension. Am. N.Y.Acad. Sci., 59:82, 1954.

• 2) 梶原長雄他:高血圧に関する研究:正常者, 本態性高血圧症患者並びにα- methyl DOPA, reserpine の投与患者の3H-DOPAの代謝, 第66回日内総会, 日内会誌, 58巻:9号, 1969年.

• 3) Frohlich, E.D.:Inhibition of adrenergic function in the treatment of hypertension. Arch. Intern. Med., 3:1033, 1974.

• 4) Nies, A.A.:Adverse reactions and interactions limiting the use of antihypertensive drugs. Am. J. Med., 58:493, 1975.

• 5) Boston Collaborative Drugs Surveillance Program:Reserpine in breast cancer. Lancet. 2:669, 1974.

P.252 掲載の参考文献

• 1) Prichard, B.N.C.:Hypotensive action of pronethalol. Br. Med. J., 1:1227-1228, 1964.

• 2) Prichard, B.N.C. and Gillam P.M.S.:Use of Propranolol (Inderal) in the treatment of hypertension. Br. Med. J., 2:725-727, 1964.

• 3) 8th World Congress of Cardiology, Abstracts-1 p. 345-361, Tokyo Japan., 1978.

• 4) Fitzgerald, J.D.:Beta adrenergic blocking drugs. Present position and future developments. Acta Cardiol., Suppl. 15:199-216, 1972.

• 5) Moran, N.C.:Beta adrenergic blockade. An Historical Review and Evaluation. In:Cardiovascular Beta adrenergic Responses P.1. Ed. Kattus, A.A. University of California.

• 6) Prichard, B.N.C. and Boakes, A.J.:The use of beta adrenoceptor blocking drugs in hypertension;a review. Curr, Med. Res. Opin., 4. Suppl. 5:51-76, 1977.

• 7) Kajiwara, N. and Sasaki, T.:Effects of several beta-blockers on hemodynamics of SHR. Jap. Heart J., 18:515-516, 1977.
  pubmed

• 8) Dusting, G.J. and Rand, M. J.:An antihypertensive action of propranolol in DOCA/salt treated rats. Clin. Exp. Pharmacol Physiol., 1:87-97, 1974.
  pubmed

• 9) Assaykeen, T.A., Clayton, P.L., Golden, A. and Ganong, W.G.:Effect of alpha and beta-adrenergic blocking agents on the renin response to hypoglycaemia and epinephrine in dogs. Endocrinology, 87:1318-1322, 1970.

• 10) Michelakis, A.M. and Mc Allister, R. G.:The effect of chronic adrenergic receptor blockade on plasma renin activity in man. J. Clin. Endocrinol., 34:386-394, 1972.

• 11) Buhler, F.R., Laragh, J.H., Baer, L., Vaughan, E.D. and Brunner, H.R.:Propranolol inhibition of renin secretion. A specific approach to diagnosis and treatment of renin-dependent hypertensive diseases. N. Engl. J. Med., 287:1209-1214, 1972.
  pubmed

• 12) Buhler, F.R., Burkart, F., Lutold, F., Kung, M., Marbet, G. and Pfistever, M.:Antihypertensive beta-blocking action as related to renin and age:apharmacologic tool to identify pathogenic mechanisms in essential hypertension. Am. J. Cardiol., 36:653-669, 1975.

• 13) Castenfors, J., Johnsson, H., and Oro, L. Effect of aiprenolol on blood pressure and plasma renin activity in hypertensive patients. Acta Med. Scand., 193:189-195, 1973.
  pubmed

• 14) Kajiwara, N.:Therapy and prognosis of hypertension in chronic nephritis. Jap. Cir. J., 39:779-786, 1975.

• 15) Morgan, T.O., Roberts, R., Carney, S.C., Louis, W.J. and Doyle, A.E.:β-adrenergic receptor blocking drugs, hypertension and plasma renin. Br. J. Clin. Pharmacol., 2:159-164, 1975.

• 16) Tarazi, R.C., Frohlich, E.D. and Dustan, H.P., Plasma volume changes with long-term beta-adrenergic blockade. Am. Heart J., 82:770-776, 1971.
  pubmed

• 17) Sedenberg-Olsen, P. and Ibsen, H.:Plasma volume and extracellular fluid volume during long-term treatment with propranolol in essential hypertension, Clin., Sci., 43:165-170, 1972.

• 18) Stern, S., Hoffman, M. and Braun, K.:Cardiovascular responses to carotid and vertebral artery infusions of Propranolol Cardiovasc. Res., 5:425-430, 1971.
  pubmed

• 19) Day, M D. and Roach, A. G.:Cardiovascular effects of β-adrenoceptor blocking agents after intracerebroventricular administration in conscious normotensive cats. Clin. Exp. Pharmacol. Physiol., 1:333-339, 1974.

• 20) Garvey, H.L and Ram, N.:Comparative antihypertensive effects and tissue distribution of beta-adrenergic blocking drugs., J. Pharmacol. Exper. Ther., 194:220-233, 1975.

• 21) Hansson, L.:Beta-adrenergic blockade in essential hypertension. Effects of propranolol on haemodynamic parameters and plasma renin activity. Acta Med. Scand., Suppl. 55:1-40, 1973.

• 22) Woolfson, A.M.J. and Knapp, M. S.:Effect of acute and chronic dosing over 24 hours. Proc. Roy. Soc. Med., 70 Suppl. 5:36, 1977.

• 23) Prichard, B.N. . and Gillam, P. M. S.:Propranolol in hypertension. Am. J. Cardiol., 18:387-391, 1966.

• 24) Dollery, C.T., Paterson, J. W. and Conolly, M. E.:Clinical pharmacology of β-blocking drugs. Clin. pharmacol. Ther., 10:765-799, 1969.

• 25) Zacharias, F.J., Cowen, K. J., Vickers, J. and Wall, B. G.:Propranolol in hypertension. A study of long-term therapy 1964-1970. Am. Heart J., 83:755-761, 1972.
  pubmed

• 26) Lyon, L. and Nerins, M. A.:Alprenolol treatment in angina pectoris. J.A.M.A., 215:1669, 1971.

• 27) Forrest, W.A.:Atotal of cases of angina pectoris treated with oxprenolol in hospital practice-a monitored release study. Br. J. Clin. Pract., 26:217-222, 1972.

• 28) Waal-Manning, H.J. and Simpson, F.O.:Practolol treatment in asthematics, Lancet. 2:1264-1265, 1971.

• 29) Zweifler, A.J. and Esler, M.:Dissociation of fall in blood pressure, renin activity and heart rate during propranolol therapy, Circulation 54:suppl II. 87, 1976.

• 30) Raftery, E.B. and Denman, A.M.:Systemic lupus erythematosus syndrome induced by practolol.. Br. Med. J., 2:452-455, 1973.
  pubmed

P.261 掲載の参考文献

• 1) Koch-Weser, J.:The comeback of hydralazine, Am. Heart J. 95:1-3, 1978.
  pubmed

• 2) Pettinger, W.A.:Recent advacnces in the treatment of hypertension. Arch. Intern. Med. 137:697-681, 1973.

• 3) Pettinger, W.A:., et al:Angiotensin antagonism and antihypertensive activity of phosphodiesterase inhibiting agents, Life Sci. 12:49-62, 1973.

• 4) Limas, C.J. & Cohn, J. N:Stimulation of vascular smooth muscle sodium, potassium-adenosine triphosphatase by vasodilators, Circulation Res. 35:601-607, 1974.

• 5) Koch-Weser, J.:Vasodilator drugs in the treatment of hypertension. Arch. Intern. Med. 133:1017-1027, 1974.
  pubmed

• 6) Veterans Administration Cooperative Study Group on Antihypertensive Agents:Effects of treatment on morbidity in hypertension, JAMA. 202:1028-1034, 1967.

• 7) Veterans Administration Cooperative Study Group on Antihypertensive Agents:Effects of treatmetn on morbidity in hypertension. JAMA. 213:1143-1152, 1970.

• 8) Hansson, L, et al:Treatment of hypertension with propranolol and hydralazine, Acta Med. Scand. 190:531-534, 1971.
  pubmed

• 9) Zacest, R., et al.:Treatment of essential hypertension with combined vasodilation and beta-adrenergic blockade, N. Engl. J. Med. 286:617-622, 1972.
  pubmed

• 10) Aenishanslin, W., et al.:Antihypertensive therapy with adrenergic β-receptor blockers and vasodilators, Eur. J. Clin. Pharmac. 4:177-180, 1972.

• 11) Winchester, J.F., et al.:Hydralazine or phentolamine as adjuncts to β-adrenoceptor blockade/thiazide therapy in hypertension, Br. J. Chn. Pharmac. 3:863-867, 1976.

• 12) Veterans Administration Cooperative Study Group on Antihypertensive Agents:Propranolol in the treatment of essential hypertension, JAMA. 237:2303-2310, 1977.

• 13) Gilmore, E., et al.:Treatment of essential hypertension with a new vasodilator in combination with β-adrenergic blockade, N. Engl. J. Med. 282:521-527, 1970.

• 14) Gottlieb, T. B., et al.:Combined therapy with vasodilator drugs and beta-adrenergic blockade in hypertension;Acomparative study of minoxidil and hydralazine, Circulation. 45:571-582, 1972,

• 15) Dormois, J.C., et al.:Minoxidil in severe hypertension..Value when conventional drugs have failed, Am. Heart J. 90:360-368, 1975.
  pubmed

• 16) Oka, M. & Makela, M.:Minoxidil in severe hypertension, Acta Med. Scand. 203:43-47, 1978.
  pubmed

• 17) Mitchell, H.C., et al.:Long-term treatment of refractory hypertensive patients with minoxidil, JAMA. 239:2131-2138, 1978.
  pubmed

• 18) Bryan, R.K., et al.:Effect of minoxidil on blood pressure and hemodynamics in severe hypertension, Am. J. Cardiol. 39:796-801, 1977.
  pubmed

• 19) Wilburn, R.L, et al.:Long-term treatment of severe hypertension with minoxidil, propranolol and furosemide, Circulation. 52:706-713, 1975.
  pubmed

• 20) Hammer, J., et al:Hemodynamic and thrapeutic effects of guancydine in hypertension, Clin. Pharmacol Ther. 12:78-90, 1971.

• 21) Page, L.B.:Drugs in the management of hypertension. part III, Am. Heart J. 92:252-259, 1976.

• 22) Hamby, W.M., et al.:Intravenous use of diazoxide in the treatment of severe hypertension, Circulation. 37:169-174, 1968.

• 23) McDonald, W.J.:Intravenous diazoxide thrapy in hypertensive crisis, Am, J. Cardiol. 40:409-415, 1977.

• 24) Finnerty, F.A. Jr., et al.:Clinical evaluation of diazoxide:A new treatment for acute hypertension, Circulation. 28:203-208, 1963.
  pubmed

• 25) Bhatia, S.K. & Frohlich, E.D.:Hemodynamic comparison of agents useful in hypertensive emergencies, Am. Heart J. 85:367-373, 1973.

• 26) Palmer, R.F. & Lasseter, K.C.:Drug therapy"Sodium Nitroprusside" N. Engl. J. Med. 292:294-297, 1975.
  pubmed

• 27) Aoki, K., et al.:Antihypertensive effect of cardiovascular Ca++-antagonist in hypertensive patients in the absence and presence of β-adrenergic blockade, Am. Heart J. 96:218-226, 1978.

P.275 掲載の参考文献

• 1) De Champlain, J., Farley, L, Cousinequ, D., van Amerigen, . M. R.:Circulating catecholamine levels in human and experimental hypertensibn. Circ. Res. 38:109, 1976.

• 2) Koch-Weser, J.:Sympathetic activity in essential hypertension. N. Engl. J. Med. 288:627, 1973.
  pubmed

• 3) Prichard, B.N.C., Tuckman, J.:Management and mechanisms of drug treatment of hypertension, in Hypertension, edited by J. Genest, E. Koiw and O. Kuchel, McGraw-Hill, N.Y., 1977, p. 1085.

• 4) Engelman, K.D., Horwitz, D., Jequier, E., Sjoerdsma, A.:Biochemical and pharmacologic effects of α-methyltyrosine in man. J. Clin. Invest. 47:577, 1968.

• 5) Enero, M.A., Langer, S.Z.:Inhibition by dopamine of 3H-noradrenaline release elicited by nerve stimulation of the isolated cat's nictitating membrane. Naunyn Schmiedebergs Arch. Pharmakol. 289:179, 1975.

• 6) Goldberg, L.I., Rick, J.H., Oparil, S.:Pharmacology of antihypertensive agents, in Hypertension edited by J. Genest, E. Koiw and O. Kuchel, McGraw-Hill, N.Y., 1977, p.990.

• 7) McMahon, F.G.:Management of essential hypertension. Futura, N.Y., 1978, p.158.

• 8) Joint international committee on detection, evaluation and treatment of high blood pressure:Report. J.A.M.A. 237:255, 1977.

• 9) Hunyor, S.N., Hansson, L, Harrison, T.S., Hoobler, S.W.:Effects of clonidine withdrawal:possible mechanisms and suggestions for management. Br. Med. J.:2:209, 1973.
  pubmed

• 10) Hess, S.M., Connamacher, R.H.:The effects of alphamethyldopa and alphamethyl-meta-tyrosine on the metabolism of norepinephrine and serotonin in vivo. J. Pharmacol Exp. Ther. 134:129, 1961.

• 11) Goodman, L.S., Gilman, A.:The pharmacological basis of therapeutics, MacMillan, N.Y., 1975, p.707.

• 12) Chamberlain, D.A., Howard, J:Guanethidine and methyldopa:a hemodynamic study. Br. Heart, J., 26:528, 1964.
  pubmed

• 13) Sannerstedt, R., Vernauskas, E., Werko, L:Hemodynamic effects of methyldopa (Aldomet) at rest and during exercise in patients with arterial hypertension. Acta. Med. Scand. 171:75, 1962.

• 14) Worlledge, S. M., Carstairs, K. C., Dacie, J. V.:Autoimmune haemolytic anemia associated with α-methyldopa therapy. Lancet, 2:135, 1966.

• 15) Meyer, J.F.:Insidius and prolonged antagonism of guanethidine by amitriptyline. J.A.M.A. 213:9, 1970.
  pubmed

P.282 掲載の参考文献

• 1) Veterans Administration Co-operative Study Group on Antihypertensive Agents:Effects of treatment on morbidity in hypertension. Results in patients with diastolic pressures averaging 115 through 129 mmHg. J.A.M.A., 202:1028, 1957.

• 2) Veterans Administration Co-operative Study Group on antihypertensive Agents:Effects of treatment on morbidity in hypertension. Results in patients with diastolic blood pressure averaging 90 through 114mmHg. J.A.M.A., 213:1143, 1970.

• 3) Stewart, I. M.G.:Compared incidence of first myocardial infarctionin hypertensive patients under treatment containing Propranolol orexcluding β-receptor blockade. Clin. Sci. Molec. Med. 51:509s, 1976.

• 4) Laragh, J.H.:Vasoconstriction-volume analysis for understanding and treating hypertension, in Hypertension Manual, edited by J.H. Laragh, York Medical Books, Dun-Donnelley, New York 1974.

• 5) Fry, J.:Natural history of hypertensiorl. A case for selective nontreatment. Lancet, 2:431, 1974.
  pubmed

• 6) Chrysant, S.G., Frohlich, E.D., Papper, S.:Why hypertension is so prevalent in the elderly and how to treat it. Geriatrics, (Oct.) 101, 1976.
  pubmed

• 7) Clinical management study group:Medical and surgical management of stroke. Stroke, 4:273, 1973.

• 8) Carter, A.:Hypotensive therapy in stroke survivors. Lancet, 1:485, 1970.
  pubmed

• 9) Richardson, D.W., Raper, A.J.:Management of complicated hypertension including hypertensive emergencies, in Hypertension:mechanisms, diagnosis, and treatment, edited by G. Onesti, A.N. Brest, F.A. Davis, Phil. 1978, p. 227.

7. 高血圧症の外科的治療

P.297 掲載の参考文献

• 1) 真崎善二郎.他:腎血管性高血圧症の腎動脈撮影像. 西日泌尿, 36:150, 1974.

• 2) Rapoport, A.:Modification of the"Howard test"for the detection of renal-artery obstruction. New Eng. J. Med., 263:1159, 1960.
  pubmed

• 3) 真崎善二郎:腎性高血圧症患者における分腎および下大 (末梢) 静脈血レニン活性. 日腎誌, 15:61, 1973.

• 4) 原 種利・他:原発性アルドステロン症の術後管理. 西日泌尿, 40:216, 1978.

• 5) 熊谷 朗・他:本邦におけるCushing 症候群320症例の臨床的検討. 日内分泌会誌, 52:551, 1976.
  Medical*Online

• 6) 渡辺 決・他:褐色細胞腫の外科的検討 (I) . 日泌尿会誌, 66:418, 1975.

• 7) Deoreo, G.A. Jr., et alal:Preoperative blood transfusion on the safe surgical management of pheochromocytoma. J. Urol., 111:715, 1974.

8. 降圧療法と予後

P.320 掲載の参考文献

• 1) 尾前照雄:臨床医学の展望-高血圧症. 日本医事新報 No.2761:3, 1977.

• 2) Dollery, C.T. and Bulpitt, C.J.:Management of hypertension, in Hypertension, ed. ey Genest, J., Koiw, E. and Kuchel, O. McGraw-Hill, New York, 1977, p. 1038.

• 3) Scciety of Actuaries:Build and blood pressure study. Scciety of Actu- aries, Chicago, 1959. (文献36より引用)

• 4) Kannel, W.B.:Importance of hypertension as a major risk factor in cardiovascular disease, in Hypertension, ed. by Genest, J., Koiw, E. and Kuchel, O. McGraw-Hill, New York, 1977, p. 888.

• 5) 尾前照雄, 竹下司恭:高血圧の予後. medicina 14:1386, 1977.

• 6) Rabkin, S.W., Mathewson, F.A.L.and Tate, R.B.:The relation of blood pressure to stroke prognosis. Ann. Intern. Med. 89:15, 1978.

• 7) Fujishima, M., Omae, T., Takeya, Y., Takeshita, M., Ogata, J. and Ueda, K.:Prognosis of occlusive cerebrovascular diseases in normotensive and hypertensive subjects. Stroke 7:472, 1976.

• 8) 尾前照雄, 竹下司恭, 山口武典, 藤島正敏, 緒方絢, 仲村吉弘:脳梗塞の 成因. 日老医誌 14:371, 1977.

• 9) Wagener, H.P. and Keith, N.M.:Cases of marked hypertension, adequate rena function and neuroretinitis. Arch. Intern. Med. 34:374, 1924.

• 10) Keith, N.W., Wagener, H.P. and Kernohan, J.W.:The syndrome of malignant hypertension. Arch. Intern. Med. 41:141, 1928.

• 11) Keith, N.M., Wagener, H.P. and Barker, N.W.:Some different types of essential hypertension:Their course and prognosis. Am. J. Med. Sci. 197:332, 1939.

• 12) Pickering, G.W.:High blood pressure, Churchill, London, 1968.

• 13) Kincaid-Smith, P., McMichael, J., and Murphy, E. A.:The clinica course and pathology of hypertension with papilloedema (malignant hypertension). Quart. J. Med. N.S. 27:117, 1958. (文献15より引用)

• 14) Smith, D.E., Odel, H.M. and Kernohan, J.W.:Causes of death in hypertension. Am. J. Med. 9:516, 1950.
  pubmed

• 15) Harington, M., Kincaid-Smith, P., and McMichael, J.:Results of treatment in malignant hypertension. A seven-year experience in 94 cases. Br. Med. J. 2:969, 1959.
  pubmed

• 16) Ueda, H., Nakajima, K., Takeda, T. and Ikeda, T.:Effectiveness ot prolonged antihypertensive treatment on survival of patients with essentialhypertension. Jap. Heart J. 5:399, 1964.

• 17) 尾前照雄, 田仲謙次郎, 飯野耕三, 柊山幸志郎, 藤島正敏, 川崎晃一:悪性 高血圧症の病態と予後. 綜合臨床 14:1903, 1965.

• 18) Hood, B., Orndahl, G. and Bjork, S.:Survival and mortality in malignant (grade IV) and grade III hypertension. Trends in consecutive, actively treated groups. Acta Med. Scand. 187:291, 1970.

• 19) Perry,, H.M. Jr., Schroeder, H.A., Catanzaro, F.J., Moore-Jones, D., and Camel, G.H.:Studies on the control of hypertension. VIIL Mortality, morbidity. and remissions during twelve years of intensive therapy. Circulation 33:958, 1966.

• 20) 川崎晃一, 柊山幸志郎, 藤見惺, 隈本健司, 瀧下修一, 野田晏宏, 前田利郎, 江藤胤尚, 尾前照雄:悪性高血圧症の病態と治療. 日本医事新報 No. 2783:10, 1977.

• 21) Bechgaard, P., Kopp, H. and Nielsen, J.:One thousand hypertensive patients followed from 16-22 years. Acta Med. Scand. Suppl 312: 175, 1956. (文献12より引用)

• 22) Veterans Administration Cooperative Study Group on Antihypertensive Agents:Effects of treatment on morbidity in hypertension. Results in patients with diastolic blood pressures averaging 115 through 129 mmHg. JAMA 202:1028, 1967.

• 23) Veterans Administration Cooperative Study Group on Antihypertensive Agents:Effects of treatment on morbidity in hypertension. II. Results in patients with diastolic blood pressure averaging 90 through 114mmHg. JAMA 213:1143, 1970.

• 24) Veterans Administration Cooperative Study Group on Antihypertensive Agents:Effects of treatment on morbidity in hypertension. III. Infuence of age, diastolic pressure, and prior cardiovascular disease; further analysis of side effects. Circulation 45:991, 1972.

• 25) U.S. Public Health Service Hospitals Cooperative Study Group:Treatment of mild hypertension. Results of a ten-year intervention trial. Circ. Res. 40 (Suppl. 1):1-98, 1977.

• 26) Carter, A.B.:Hypotensive therapy in stroke survivors. Lancet 1:485, 1970.
  pubmed

• 27) Beevers, D.G., Fairman, M.J., Hamilton, M. and Harpur, J. E.:Antihypertensive treatment and the course of established cerebral vascular disease. Lancet 1:1407, 1973.
  pubmed

• 28) Hypertension-Stroke Cooperative Study Group:Effect of antihypertensive treatment on stroke recurrence. JAMA 229:409, 1974.

• 29) Breckenridge, A., Dollery, C.T. and Parry, E.H.O.:Prognosis of treated hypertension. Changese in life expectancy and causes of death between 1952 and 1967. Quart. J. Med. N.S. 39:411, 1970.

• 30) Page, I. H. and Dustan, H. P.:Persistence of normal blood pressure after discontinuing treatment in hypertensive patients. Circulation 25:433, 1962.

• 31) Veterans Administration Cooperative Study Group on Antihypertensive Agents:Return of elevated blood pressure after withdrawal of antihy-pertensive drugs. Circulation 51:1107, 1975.

• 32) Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure:Report of the Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure. A cooperative study. JAMA 237:255, 1977.
  pubmed

• 33) Julius, S. and Schork, M.A.:Borderline hypertension-A critical review. J. Chron. Dis. 23:723, 1971.
  pubmed

• 34) Julius, S.:Borderline hypertension. Med. Clin. North. Am. 61:495, 1977.
  pubmed

• 35) Jackson, G., Pierscianowski, T.A., Mahon, W. and Condon, J.:Inappropriate anti-hypertensive therapy in the elderly. Lancet 2:1317, 1976.

• 36) Itskovitz, H.D.:Aperspective of hypertension, its epidemiology and complications:Implications for antihypertensive drug therapy, in New antihypertensive drugs, ed. by Scriabine, A. and Sweet, C.S.:Spectrum Publications, New York, 1976, p.3.

• 37) Robinson, S.K.:Coronary artery disease and antihypertensive drugs. J. Clin. Pharmacol. 12:123, 1976.

• 38) Berglund, G., Wilhelmsen, L., Sannerstedt, R., Hansson, L, Andersson, O., Sivertsson, R., Wedel, H. and Wikstrand, J.:Coronary heart-disease after treatment of hypertension. Lancet 1:1, 1978.
  pubmed

• 39) Ibrahim, M.M., Tarazi, R.C., Dustan, H.P. and Gifford, R.W. Jr.:Electrocardiogram in evaluation of resistance to antihypertensive therapy. Arch. Intern. Med. 137:1125, 1977.
  pubmed

• 40) Brunner, H.R., Laragh, J.H., Baer, L., Newton, M. A., Goodwin, F.T., Krakoff, J.R., Bard, R.H. and Buhler, F. R.:Essential hypertension:Renin and aldosterone, heart attack and stroke. N. Engl. J. Med. 286:441, 1972.

• 41) Kaplan, N.M.:The prognostic impliations of plasma renin in essential hypertension. JAMA 231:167, 1975.